Abivax S.A. (ABVX) Stock

About Abivax S.A.

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Abivax S.A. is headquartered in FR.

Abivax S.A. (ABVX) stock trades at $136.94 with a market capitalization of $10.06B. The stock is valued at a negative price-to-earnings (P/E) ratio of -24.37, reflecting a net loss over the last twelve months, price-to-book of 17.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.25 and $148.83, and currently trades 8.0% below its 52-week high.

On profitability, Abivax S.A. generates a return on equity (ROE) of -165.19% (negative, reflecting a net loss), return on capital employed of -48.08%.

Official website: www.abivax.com

Abivax S.A. by the numbers, 2016–2025

Between 2016 and 2025 Abivax S.A. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-336.0M.

On a trailing twelve-month basis to Dec '25, revenue is $0 and net profit $-427.0M.

Borrowings stand at $46.0M, cash on hand is $530.2M, cash from operations was $-156.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -322.3% over five years, and was -73.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, 1447.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Abivax S.A. (ABVX) — frequently asked questions